RASUVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RASUVO (RASUVO).
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
| Metabolism | Adalimumab undergoes catabolism to small peptides and amino acids. No specific metabolic pathways or enzymes have been identified. |
| Excretion | Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage. |
| Half-life | Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate. |
| Protein binding | Approximately 80-90%, primarily to albumin. |
| Volume of Distribution | Estimated 6 L (not L/kg; body weight-normalized data not available); indicates distribution primarily within vascular space. |
| Bioavailability | Subcutaneous: approximately 80%. |
| Onset of Action | Subcutaneous: Clinical response (ACR20) observed as early as 4 weeks; maximal effect by 12-24 weeks. |
| Duration of Action | Approximately 4 weeks for subcutaneous injection at recommended dosing interval; trough levels remain therapeutic. Dosing every 2 or 4 weeks maintains efficacy. |
Subcutaneous injection: 200 mg once weekly.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment is recommended for patients with renal impairment, including those on dialysis. |
| Liver impairment | No dose adjustment is recommended for patients with hepatic impairment, including Child-Pugh Class A, B, or C. |
| Pediatric use | Approved for adolescents (age ≥12 years) weighing ≥60 kg: 200 mg subcutaneously once weekly. Not approved for children <12 years. |
| Geriatric use | No specific dose adjustment is recommended; use with caution due to higher infection risk and potential comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RASUVO (RASUVO).
| Breastfeeding | Methotrexate is excreted into breast milk at low concentrations; M/P ratio is approximately 0.08. Due to potential for accumulation and serious adverse effects (immunosuppression, neutropenia) in the nursing infant, breastfeeding is contraindicated during RASUVO therapy. |
| Teratogenic Risk | RASUVO (methotrexate) is contraindicated in pregnancy. First trimester exposure is associated with severe teratogenic effects including craniofacial, cardiac, and central nervous system malformations (methotrexate embryopathy). Second and third trimester use can cause fetal toxicity, intrauterine growth restriction, and neonatal death. Absolute contraindication in all trimesters. |
■ FDA Black Box Warning
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue RASUVO if a serious infection develops. Perform test for latent TB; if positive, start treatment for TB prior to starting RASUVO. Monitor for signs of active TB during and after treatment, even if initial test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers.
| Serious Effects |
["Known hypersensitivity to adalimumab or any component of the formulation","Active serious infections including sepsis and tuberculosis"]
| Precautions | ["Serious infections (including TB, invasive fungal, and other opportunistic infections)","Malignancies (including lymphoma, leukemia, and solid tumors)","Hepatitis B virus reactivation","Demyelinating disease","Heart failure (worsening or new onset)","Hematological reactions (pancytopenia, aplastic anemia)","Lupus-like syndrome","Hypersensitivity reactions (including anaphylaxis)","Vaccinations (avoid live vaccines)","Risk of infection with concurrent use of other biologics"] |
Loading safety data…
| Fetal Monitoring | Pregnancy testing prior to initiation and monthly during therapy. Regular monitoring of complete blood count, liver function tests, serum creatinine, and chest imaging (due to risk of pneumonitis). Fetal ultrasound if unintentional exposure occurs. |
| Fertility Effects | Methotrexate may impair fertility in both males and females. In women, it can cause amenorrhea, ovulatory dysfunction, and premature ovarian failure. In men, oligospermia and decreased sperm motility have been reported; effects are generally reversible after discontinuation. |